Atezolizumab is the most studied anti-PDL1 antibody; it is thought that atezolizumab is more tolerable than anti-PD1 antibodies, and has been approved mainly for the treatment of advanced urothelial cancer, lung cancer, melanoma, and hepatocellular cancer. Here, PDCD1 is linked to hepatocellular carcinoma.